In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Plavix: As Bristol Swoons, Broad Implications

Executive Summary

The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.
Advertisement

Related Content

Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Pfizer Deal Highlights Bristol's Biotech Swagger
Baked-In Goodness: Shire Buys New River for $2.6 Billion
A Look Back at 2006: The Pipeline Challenge
Pfizer's Change Management: Unfamiliar Faces
The Outsourcing Dilemma
Authorized Generics: Band-Aid or Strategy?
Bristol's Bid for Revival
Bayer: Will the Pillars Crumble?
Nous Voici! Sanofi's Leap to the World Stage

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel